Cytomegalovirus Retinitis: Clinical Trials

64 trials for Cytomegalovirus Retinitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

57 completed, 3 unknown, 2 recruiting, 2 withdrawn. 23 Not applicable, 13 Phase 2, 11 Phase 3, 8 Phase 1, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable23Completed 20, Unknown 2, Recruiting 1
Phase 213Completed 12, Withdrawn 1
Phase 311Completed 10, Unknown 1
Phase 18Completed 7, Withdrawn 1
Phase 43Completed 3
Early Phase 11Recruiting 1

Follow Cytomegalovirus Retinitis: new trials by email Literature Review of Cytomegalovirus Retinitis trials Research Report on Cytomegalovirus Retinitis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
LB-DTK-CMV - CMV Retinitis
Not applicableRecruitingLucasBio52026-04-272026-07-01
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
2% Ganciclovir Eye Drops - Cytomegalovirus Retinitis, Ganciclovir Eye Drops
Early Phase 1RecruitingTianjin Medical University152023-07-012023-06-23
Deep Learning-based System and AIDS-related Cytomegalovirus Retinitis
Cytomegalovirus Retinitis
CompletedKuifang Du502021-04-012021-07-21
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care: - Adenovirus, Anesthesia
CompletedDaniel Benjamin35202011-11-012023-09-06
Efficacy of Elevated CD4 Counts on CMV Retinitis
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
CompletedNational Eye Institute (NEI)152004-07-012008-03-04
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
Cidofovir pharmacokinetics - Cytomegalovirus Retinitis, Acute Renal Failure
Phase 4CompletedMedical University of Vienna12002-03-012013-06-05
Longitudinal Study of Ocular Complications of AIDS (LSOCA)
HIV Infections, Acquired Immunodeficiency Syndrome
CompletedJohns Hopkins Bloomberg School of Public Health23921998-08-012015-06-12
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Ganciclovir implant and oral ganciclovir, Cidofovir intravenous - Cytomegalovirus Retinitis, HIV Infections
Phase 3CompletedJohns Hopkins Bloomberg School of Public Health611997-05-012016-03-14
Immune Activity Against CVM Retinitis
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
CompletedNational Eye Institute (NEI)151997-02-012008-03-04
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Valganciclovir, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections
Phase 3CompletedHoffmann-La Roche1997-01-012017-05-17
Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)
MSL-109, Placebo - HIV Infections, Cytomegalovirus Retinitis
Phase 2 / Phase 3CompletedJohns Hopkins Bloomberg School of Public Health2091995-09-012015-11-17
Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis
cidofovir - Cytomegalovirus Retinitis, Acquired Immunodeficiency Syndrome
Phase 2CompletedNational Center for Research Resources (NCRR)901995-03-012005-06-24
Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Cidofovir - HIV Infections, CMV Cytomegalovirus Retinitis
Phase 2 / Phase 3CompletedJohns Hopkins Bloomberg School of Public Health641994-04-012015-11-17
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
Ganciclovir, Foscarnet - HIV Infections, Acquired Immunodeficiency Syndrome
Phase 3CompletedJohns Hopkins Bloomberg School of Public Health2791992-12-012015-09-14
Ganciclovir Implant Study for Cytomegalovirus Retinitis
Sustained-Release Intraocular Drug Delivery System - HIV Infections, Acquired Immunodeficiency Syndrome
Phase 3CompletedNational Eye Institute (NEI)1992-10-012009-09-17
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
Foscarnet, Ganciclovir - HIV Infections, Cytomegalovirus Retinitis
Phase 3CompletedJohns Hopkins Bloomberg School of Public Health2341990-03-012015-10-22
A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy
Cytomegalovirus Retinitis, HIV Infections
CompletedNational Institute of Allergy and Infectious Diseases (NIAID)752008-07-30
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes
Ganciclovir - Cytomegalovirus Retinitis, HIV Infections
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)252021-11-04
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir
Foscarnet sodium - Cytomegalovirus Retinitis, HIV Infections
Phase 2WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2021-11-04
Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
Zidovudine, Acyclovir - Cytomegalovirus Retinitis, HIV Infections
Not applicableCompletedNational Institute of Allergy and Infectious Diseases (NIAID)252021-11-02

Showing 20 of 64. Sign in to see all of them.

Narrower conditions

HIV Infections (57)  ·  Acquired Immunodeficiency Syndrome (46)  ·  Retinitis (36)  ·  Cytomegalovirus Infections (32)  ·  Multiple Acyl Coenzyme A Dehydrogenase Deficiency (30)  ·  AIDS-Related Opportunistic Infections (25)  ·  Neutropenia (2)  ·  Acute Kidney Injury (1)  ·  Adenoviridae Infections (1)  ·  Anxiety Disorders (1)  ·  Arrhythmias, Cardiac (1)  ·  Autistic Disorder (1)  ·  Autoimmune Diseases (1)  ·  Bipolar Disorder (1)

Broader conditions

DNA Virus Infections (64)  ·  Eye Diseases (64)  ·  Eye Infections (64)  ·  Eye Infections, Viral (64)  ·  Herpesviridae Infections (64)  ·  Virus Diseases (64)  ·  Infections (63)  ·  Retinal Diseases (63)  ·  Urogenital Diseases (62)  ·  Genital Diseases (61)  ·  Immune System Diseases (61)  ·  RNA Virus Infections (61)  ·  Blood-Borne Infections (60)  ·  Communicable Diseases (60)  ·  Immunologic Deficiency Syndromes (60)

Interventions

Ganciclovir (27)  ·  Foscarnet (13)  ·  Cidofovir (10)  ·  Probenecid (5)  ·  fomivirsen (4)  ·  sevirumab (4)  ·  Valganciclovir (3)  ·  Zidovudine (3)  ·  sargramostim (2)  ·  Acyclovir (1)  ·  Alfentanil (1)  ·  Amikacin (1)  ·  Aminocaproic Acid (1)  ·  Antibodies, Monoclonal (1)  ·  Bosentan (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (21)  ·  Hoffmann-La Roche (9)  ·  Johns Hopkins Bloomberg School of Public Health (6)  ·  Astra USA (4)  ·  Ionis Pharmaceuticals, Inc. (4)  ·  Gilead Sciences (3)  ·  National Eye Institute (NEI) (3)  ·  Roche Global Development (3)  ·  Agouron Pharmaceuticals (1)  ·  American National Red Cross (1)  ·  Chiron Corporation (1)  ·  Daniel Benjamin (1)  ·  Kuifang Du (1)  ·  LucasBio (1)  ·  Medical University of Vienna (1)

Countries

United States (51)  ·  Canada (6)  ·  China (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Israel (1)  ·  Puerto Rico (1)  ·  Singapore (1)  ·  South Korea (1)

Top investigators

Douglas Jabs, MD (2)  ·  Hardy WD (2)  ·  MA Jacobson (2)  ·  Borucki M (1)  ·  Brosgart C (1)  ·  C Crumpacker (1)  ·  CA Benson (1)  ·  CS Crumpacker (1)  ·  Chao Chen (1)  ·  Chi Hornik, PharmD (1)  ·  Craig C (1)  ·  Curtis Meinert, PhD (1)  ·  Dankner W (1)  ·  David V. Weinberg (1)  ·  Doug A Jabs, MD (1)

Results publications

PMID 31042791, PMID 11919489, PMID 12232843, PMID 12559647, PMID 15498605, PMID 16192248, PMID 24614374, PMID 24949994, PMID 26039810, PMID 26926644, PMID 27522443, PMID 28137820, PMID 28290120, PMID 28779462, PMID 29084742, PMID 29271816, PMID 29435949, PMID 29677389, PMID 30790601, PMID 31317556, PMID 31548185, PMID 31814149, PMID 32324313, PMID 32497307, PMID 33029806, PMID 33903114, PMID 34302290, PMID 35370711, PMID 35491971, PMID 41247430, PMID 9400786

NIH funding

U10EY008057 (3), U01AI027668 (1)